IRadimed Corp (IRMD) is now in the Overvalued zone, suggesting that its current forward PE ratio of 53.06 is considered Overvalued compared with the five-year average of 37.60. The fair price of IRadimed Corp (IRMD) is between 65.86 to 95.60 according to relative valuation method. Compared to the current price of 103.74 USD , IRadimed Corp By Overvalued By 8.52%.

Relative Value

Fair Zone

65.86-95.60

Current Price：103.74

8.52%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is IRadimed Corp (IRMD) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

IRadimed Corp (IRMD) has a current Price-to-Book (P/B) ratio of 12.35. Compared to its 3-year average P/B ratio of 8.23, the current P/B ratio is approximately 50.06% higher. Relative to its 5-year average P/B ratio of 7.50, the current P/B ratio is about 64.73% higher. IRadimed Corp (IRMD) has a Forward Free Cash Flow (FCF) yield of approximately 1.21%. Compared to its 3-year average FCF yield of 1.78%, the current FCF yield is approximately -31.88% lower. Relative to its 5-year average FCF yield of 1.91%, the current FCF yield is about -36.44% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for IRMD competitors is 66.89, providing a benchmark for relative valuation. IRadimed Corp Corp (IRMD.O) exhibits a P/S ratio of 13.81, which is -79.35% above the industry average. Given its robust revenue growth of 17.03%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of IRMD increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of IRMD in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is IRMD currently overvalued or undervalued?

What is IRadimed Corp (IRMD) fair value?

IRMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of IRadimed Corp (IRMD) is between 65.86 to 95.60 according to relative valuation method.

How does IRMD's valuation metrics compare to the industry average?

The average P/S ratio for IRMD's competitors is 66.89, providing a benchmark for relative valuation. IRadimed Corp Corp (IRMD) exhibits a P/S ratio of 13.81, which is -79.35% above the industry average. Given its robust revenue growth of 17.03%, this premium appears unsustainable.

What is the current P/B ratio for IRadimed Corp (IRMD) as of Mar 02 2026?

As of Mar 02 2026, IRadimed Corp (IRMD) has a P/B ratio of 12.35. This indicates that the market values IRMD at 12.35 times its book value.

What is the current FCF Yield for IRadimed Corp (IRMD) as of Mar 02 2026?

As of Mar 02 2026, IRadimed Corp (IRMD) has a FCF Yield of 1.21%. This means that for every dollar of IRadimed Corp's market capitalization, the company generates 1.21 cents in free cash flow.

What is the current Forward P/E ratio for IRadimed Corp (IRMD) as of Mar 02 2026?

As of Mar 02 2026, IRadimed Corp (IRMD) has a Forward P/E ratio of 53.06. This means the market is willing to pay $53.06 for every dollar of IRadimed Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for IRadimed Corp (IRMD) as of Mar 02 2026?

As of Mar 02 2026, IRadimed Corp (IRMD) has a Forward P/S ratio of 13.81. This means the market is valuing IRMD at $13.81 for every dollar of expected revenue over the next 12 months.

IRMD Valuation